This is a non-core endpoint: only basic statistics are computed.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters
Medicine purchases: ATC
A10BH
1 out of 7 registries used, show all original rules.
21626
Check minimum number of events
Min. number of events
3
21626
Include endpoints None
21626
Remove individuals based on genotype QC
20866
GLP1ANA
Control definitions
Control exclude
DIAB_MED_OTHER
Extra metadata
First used in FinnGen datafreeze
DF2
Show upset plot detailing case counts by codes
Or the full data table
Similar endpoints
↥List of similar endpoints to
Glucagon-like peptide-1 (GLP-1) analogues
based on the number of shared cases.
Broader endpoints:
- Other (not insulin) diabetes medications
- Diabetes medication
- Type 2 diabetes
- Diabetes mellitus
- Endocrine, nutritional and metabolic diseases
Narrower endpoints:
None
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 20866 | 9112 | 11754 |
| Unadjusted prevalence (%) | 5.06 | 3.96 | 6.47 |
| Mean age at first event (years) | 65.49 | 65.03 | 65.84 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: GLP1ANA – Glucagon-like peptide-1 (GLP-1) analogues
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Glucagon-like peptide-1 (GLP-1) analogues
↥Endpoint not on priority list, no data to show.